Another Chinese Phase I study is currently recruiting 40 patients with advanced solid tumors (including BC) to investigate the efficacy of TILs and CAR-TILs against several molecular targets, including ROR1, MUC1, HER-2, Mesothelin, PSCA, EGFR, GD1, GPC3, Lewis-Y, AXL, Claudin18.2/6, and B7-H3. This evidence concerns the gene AXL and breast cancer.